Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
Authors: James V. Freeman, Mintu P. Turakhia
Journal: Annals of Internal Medicine (2011)

Letters19 April 2011Dabigatran Compared With Warfarin for Stroke Prevention in Atrial FibrillationJames V. Freeman, MD, MPH and Mintu P. Turakhia, MD, MASJames V. Freeman, MD, MPHFrom Stanford University School of Medicine, Stanford, CA 94305-5406; and Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304. and Mintu P. Turakhia, MD, MASFrom Stanford University School of Medicine, Stanford, CA 94305-5406; and Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-154-8-201104190-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The U.S. Food and Drug Administration approved dabigatran, 150 mg twice daily but not 110 mg twice daily, to prevent thromboembolism in patients with atrial fibrillation. The drug manufacturer, Boehringer Ingelheim (Ingelheim am Rhein, Germany), announced a wholesale price of $6.75 per day in the United States. After retail markup, the cost to the consumer is approximately $8.00 per day, less than our published base-case estimate of $13.00 per day. In addition, the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial investigators reported newly identified adverse effects in both the warfarin and dabigatran treatment groups of their ...References1. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial [Letter]. N Engl J Med. 2010;363:1875-6. [PMID: 21047252] CrossrefMedlineGoogle Scholar2. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-27. [PMID: 20352166] CrossrefMedlineGoogle Scholar3. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363:1791-800. [PMID: 21047223] CrossrefMedlineGoogle Scholar4. Pradaxa: highlights of prescribing information. Boehringer Ingelheim Pharmaceuticals. October 2010. Accessed at www.accessdata.fda.gov/drugsatfda_docs/label/2010/022512s000lbl.pdf on 24 February 2011. Google Scholar Author, Article, and Disclosure InformationAffiliations: From Stanford University School of Medicine, Stanford, CA 94305-5406; and Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-1416. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation James V. Freeman , Ruo P. Zhu , Douglas K. Owens , Alan M. Garber , David W. Hutton , Alan S. Go , Paul J. Wang , and Mintu P. Turakhia Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation Alan M. Berg Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation David B. Edwards and John Silverberg Metrics Cited ByDabigatran for the prevention and treatment of thromboembolic disordersEfficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age SubgroupsCost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspectiveA Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial FibrillationCost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial FibrillationStop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature reviewCost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in SwedenOral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial FibrillationCost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in SpainAnálisis coste-efectividad de dabigatrán para la prevención de ictus y embolia sistémica en fibrilación auricular no valvular en EspañaDabigatran EtexilateIs Dabigatran Cost Effective Compared With Warfarin for Stroke Prevention in Atrial Fibrillation?Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic AttackCost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillationDabigatranThe Relative Cost-Effectiveness of AnticoagulantsQuestions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. 19 April 2011Volume 154, Issue 8Page: 570-571KeywordsAtrial fibrillationDrugsHemorrhageIschemic strokeMyocardial infarctionStrokeThromboembolismTransient ischemic attacks ePublished: 19 April 2011 Issue Published: 19 April 2011 CopyrightCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...